Replies to post #4163 on AVANIR PHARMACEUTICALS (AVNR)

[Prudent Capitalist]

I disagree. Any analysis that simpy tracks trailing quarters' numbers, without factoring in the projected sharp increases in revenue going forward as a result of the commercial roll-out of Nuedexta, is flawed.